CART Cell Toxicities and Management
<p id="p1">Chimeric antigen receptor T-cell (CART) therapy is a novel therapeutic modality utilized for managing relapsed/refractory hematologic cancers. This approach entails the genetic modification of either autologous or allogeneic T-cells to incorporate chimeric antigen receptor (CAR) proteins,...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2025
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/1201549 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | <p id="p1">Chimeric antigen receptor T-cell (CART) therapy is a novel therapeutic modality utilized for managing relapsed/refractory hematologic cancers. This approach entails the genetic modification of either autologous or allogeneic T-cells to incorporate chimeric antigen receptor (CAR) proteins, enabling them to target specific proteins present on the surface of cancer cells and causing cytotoxicity. Despite its promising therapeutic outcomes, there is a notable drawback wherein these modified cells may also attack normal tissue cells expressing similar surface proteins. This phenomenon of cross-reactivity often leads to adverse events (AEs), resulting in significant mortality and morbidity. This chapter focuses on the assessment and management of CART therapy-related toxicities.</p> |
|---|---|
| ISBN: | 978-0-85466-524-2 |
| DOI: | 10.5772/intechopen.1008565 |